| アブストラクト | Though triazole antifungals are the first choice for preventing and treating invasive fungal infections, periostitis caused by voriconazole has been described in emerging case reports; however, no studies exist on this association in real-world clinical settings. Our study aimed to identify the association between periostitis and triazole antifungals by analyzing data from the FDA Adverse Event Reporting System (FAERS). We extracted and analyzed reports on the association between periostitis and triazole antifungals in FAERS from the first quarter of 2004 to the second quarter of 2022 using OpenVigil 2.1. Disproportionality analysis was performed to evaluate the association between periostitis and triazole antifungals, and chi-squared (chi(2)), relative reporting ratio (RRR), reporting odds ratio (ROR), proportional reporting ratio (PRR), and Bayesian confidence propagation neural networks (BCPNN) of information components (IC) were reported. In total, 143 patients experienced periostitis while using voriconazole. Disproportionality analysis identified an association between periostitis and voriconazole (chi(2) = 82,689.0, RRR = 583.6, 95%CI [472.4, 721.1], PRR = 1808.9, 95%CI [1356.0, 2412.9], ROR = 1831.7, 95%CI [1371.6, 2446.3], IC = 9.2, 95%CI [8.6, 9.8]). However, no safety signals were observed between periostitis and other triazole antifungals. When stratified by sex and age, disproportionality analysis identified positive signals between periostitis and voriconazole. The possible association between periostitis and voriconazole should attract sufficient attention in clinical practice. Alternative treatment with other triazole antifungals can be considered, and causality needs to be verified in further prospective studies. |
|---|
| ジャーナル名 | Scientific reports |
|---|
| Pubmed追加日 | 2023/3/20 |
|---|
| 投稿者 | Li, Hailong; Zhang, Miao; Jiao, Xuefeng; Zhu, Yu; Liu, Yan; Zeng, Linan; Wang, Huiqing; Zhang, Lei; Zhang, Wei; Zhang, Lingli |
|---|
| 組織名 | Department of Pharmacy, West China Second University Hospital, Sichuan;University, Chengdu, China.;Evidence-Based Pharmacy Center, West China Second University Hospital, Sichuan;NMPA Key Laboratory for Technical Research On Drug Products In Vitro and In Vivo;Correlation, Chengdu, China.;Key Laboratory of Birth Defects and Related Diseases of Women and Children,;Ministry of Education, Sichuan University, Chengdu, China.;West China School of Pharmacy, Sichuan University, Chengdu, China.;Department of Pediatrics, West China Second University Hospital, Sichuan;College of Computer Science, Sichuan University, Chengdu, China.;West China Biomedical Big Data Center, West China Hospital, Sichuan University,;Chengdu, China. zhangwei@wchscu.cn.;Medical Big Data Center, Sichuan University, Chengdu, China. zhangwei@wchscu.cn.;University, Chengdu, China. zhanglingli@scu.edu.cn.;Correlation, Chengdu, China. zhanglingli@scu.edu.cn.;zhanglingli@scu.edu.cn. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/36934109/ |
|---|
